Antibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB781-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Canine IFN-gamma Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects canine IFN-gamma in direct ELISAs and Western blots. In direct ELISAs, this antibody shows approximately 75% cross-reactivity with recombinant porcine IFN-gamma and no cross-reactivity with IFN-gamma from human, mouse, feline, rat, or rhesus macaque.
- Reactivity
- Canine
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
P42161
- Isotype
- IgG
- Antibody clone number
- 142529
- Vial size
- 100 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function.
Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs.
Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs.
Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
Schaut RG, Grinnage-Pulley TL, Esch KJ, Toepp AJ, Duthie MS, Howard RF, Reed SG, Petersen CA
Vaccine 2016 Oct 17;34(44):5225-5234
Vaccine 2016 Oct 17;34(44):5225-5234
Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
Petitdidier E, Pagniez J, Papierok G, Vincendeau P, Lemesre JL, Bras-Gonçalves R
PLoS neglected tropical diseases 2016 May;10(5):e0004614
PLoS neglected tropical diseases 2016 May;10(5):e0004614
Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function.
Esch KJ, Juelsgaard R, Martinez PA, Jones DE, Petersen CA
Journal of immunology (Baltimore, Md. : 1950) 2013 Dec 1;191(11):5542-50
Journal of immunology (Baltimore, Md. : 1950) 2013 Dec 1;191(11):5542-50
Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G
Vaccine 2007 May 22;25(21):4223-34
Vaccine 2007 May 22;25(21):4223-34
Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs.
Fujiwara RT, Loukas A, Mendez S, Williamson AL, Bueno LL, Wang Y, Samuel A, Zhan B, Bottazzi ME, Hotez PJ, Bethony JM
Vaccine 2006 Jan 23;24(4):501-9
Vaccine 2006 Jan 23;24(4):501-9
Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs.
Strauss-Ayali D, Baneth G, Shor S, Okano F, Jaffe CL
International journal for parasitology 2005 Jan;35(1):63-73
International journal for parasitology 2005 Jan;35(1):63-73
Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
Lemesre JL, Holzmuller P, Cavaleyra M, Gonçalves RB, Hottin G, Papierok G
Vaccine 2005 Apr 22;23(22):2825-40
Vaccine 2005 Apr 22;23(22):2825-40
No comments: Submit comment
No validations: Submit validation data